Email Alerts
Investor Relations
Press Releases
- Boston Therapeutics Reports First Quarter 2013 Results
May 15, 2013, 4:10 PM EDT - Boston Therapeutics Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes
Apr 11, 2013, 7:00 AM EDT - Boston Therapeutics Featured in Four Publications
Apr 8, 2013, 7:50 AM EDT - Boston Therapeutics Reports Full Year 2012 Financial Results
Apr 4, 2013, 4:10 PM EDT - Boston Therapeutics Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: To Accelerate Commercialization of PAZ320 & IPOXYN(TM)
Mar 27, 2013, 7:00 AM EDT - Boston Therapeutics Appoints Peter Sheehan, M.D. as Medical Director
Mar 12, 2013, 7:00 AM EDT - Boston Therapeutics Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes
Feb 26, 2013, 7:00 AM EST - Boston Therapeutics Announces Clinical Study Final Results Indicate That SUGARDOWN(R) Reduced the Post-Meal Elevation of Blood Glucose by up to 61% in Healthy Volunteers
Jan 28, 2013, 7:30 AM EST - Boston Therapeutics Approved in France to Initiate a Clinical Trial With SUGARDOWN(R) in Patients With Type II Diabetes
Dec 19, 2012, 7:30 AM EST - Boston Therapeutics to Present Corporate Update at the SeeThruEquity Smallcap & Microcap Investor Summit
Nov 29, 2012, 7:00 AM EST
© Copyright 2013 Boston Therapeutics, Inc.
Website by Equisolve
Website by Equisolve
